ArticleMolecular therapy. Nucleic acids2026
Evaluation and forecasting of siRNA delivery technologies: An analysis of hierarchical decision model based on patent data.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small interfering RNA (siRNA) represents a transformative modality in next-generation therapeutics, yet challenges in delivery efficiency still limit its clinical translation. Systematic evaluation tools are needed to reveal technological progress in this area. Given the innovation momentum inherent in patents, this study develops a patent-based evaluation model for siRNA delivery technologies from a technology management perspective. By integrating the Hierarchical Decision Model (HDM) with patent landscape analysis, the model incorporates 15 multidimensional criteria across technological, commercial, and legal perspectives, with the commercial perspective assigned the greatest weight (41%), followed by technical (32%) and legal (27%) perspectives. A large-scale dataset comprising 20,319 siRNA delivery-related patent documents was quantitatively assessed using this model. The results reveal that high-value patents are primarily concentrated in lipid-based carriers and ligand-siRNA conjugates, with firms such as Alnylam and Arbutus emerging as dominant innovation leaders. Furthermore, the analysis highlights that therapeutic indication, assignee's technological accumulation, technological impact, and drug delivery method are key drivers of patent value. Overall, the proposed model supports strategic decision-making in patent portfolio management and technology forecasting by identifying high-value innovations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.